How comparing works here
How do I compare two companies?
Type the tickers into the box above — up to five at once. Every row is read from the companies' own annual filings, so a comparison shows the same measure computed the same way for each of them rather than whatever each company chose to highlight.
Can I compare an ETF with a stock?
Yes, and the table changes to suit. Two funds are compared on cost, income, spread and record, because revenue growth and debt mean nothing for a fund. A fund against a company shows only what both of them have.
Side by side
Compare
Put up to 4 companies, funds, commodities or coins next to each other — health, valuation, growth and performance.
Every row is computed the same way for every column, from each company's own annual filing, so a comparison is not a collection of whichever figures each of them chose to put in a press release. Funds are compared on what a fund is actually judged on: cost, income, spread and record.
Relative performance
Rebased so every symbol starts at 0%
Loading price history…
Side by side
Latest annual figures from each company's filings
| Metric | INCYINCYTE CORP | NTRANatera, Inc. | RVMDRevolution Medicines, Inc. | BIIBBIOGEN INC. | Median of the restexcluding INCY |
|---|---|---|---|---|---|
| Type | Company | Company | Company | Company | |
| Price | $116.93▲ 3.49 (3.08%) | $401.37▼ 12.01 (2.91%) | $194.28▼ 2.27 (1.15%) | $240.98▼ 2.12 (0.87%) | |
| Health scoreComposite of profitability, growth, debt and accounting quality. | 10.0/10 | 4.7/10 | 2.0/10 | 9.0/10 | 4.7/10 |
| Market value | $23.21B | $56.07B | $38.27B | $35.38B | |
| Revenue | $5.14B | $2.31B | $0.00 | $9.89B | |
| Profit | $1.29B | -$208.2M | -$1.13B | $1.29B | |
| Revenue growthChange in sales versus the prior year. | 21.2% | 35.9% | — | 2.2% | 19.1% |
| Gross marginShare of sales left after the direct cost of producing them. | 92.8% | — | — | 75.7% | 75.7% |
| Operating marginShare of sales left after running the business, before interest and tax. | 29.5% | -13.4% | — | — | -13.4% |
| Profit marginProfit kept from each dollar of sales. | 25.0% | -9.0% | — | 13.1% | 2.0% |
| Free cash flow marginCash left after capital spending, as a share of sales. | — | 4.7% | — | 20.7% | 12.7% |
| Return on equityProfit against the owners' stake in the company. | 24.9% | -12.2% | -69.3% | 7.1% | -12.2% |
| Return on invested capital (approx.)Operating profit after tax against equity plus debt, less cash. Cash here excludes short-term investments, so this runs low for cash-rich companies. | 56.6% | -34.2% | -74.9% | — | -54.5% |
| P/E ratioPrice paid per dollar of annual profit. | 18.04x | — | — | 27.36x | 27.36x |
| EV / EBITDA (approx.)Market value plus debt less cash, against operating profit before depreciation. Cash excludes short-term investments, so this runs high for cash-rich companies. | — | — | — | — | — |
| Price to book | 4.49x | 32.74x | 23.46x | 1.94x | 23.46x |
| Debt to equityTotal liabilities compared with owners' stake. | 0.35x | 0.40x | 0.44x | 0.61x | 0.44x |
| Piotroski F-ScoreNine checks of financial strength. Higher is stronger. | 6/8 | 2/7 | 1/7 | 6/9 | 2.0 |
| Bankruptcy riskAltman Z-Score zone. | safe | distress | safe | safe |
How INCY compares with the others
- INCY's operating margin of 29.5% is higher than the other company selected (-13.4%).
- Its revenue grew faster than the median of the other companies selected: 21.2% against 19.1%.
- It trades at a lower P/E than the other company selected: 18.0x against 27.4x.
- Its liabilities are lower relative to equity than the median of the other companies selected: 0.3x against 0.4x.
Measured against the other companies entered, from each one's latest annual filing. A difference describes the companies; it does not rank them.